La catena delle opzioni mostra i dati chiave delle opzioni azionarie di MeiraGTx Hldgs a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per MeiraGTx Hldgs..

MeiraGTx Hldgs (NASDAQ:MGTX) Azioni, Catena delle Opzioni

MeiraGTx Hldgs

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

MeiraGTx Holdings PLC

D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) with a Buy and maintains $16 price target.

News

Price Target

Analyst Ratings

FBLG

D. Boral Capital Maintains Buy on FibroBiologics, Maintains $16 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar initiates coverage on vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) with a Buy rating and announces Price Target of $36.

Initiation

VTVT

HC Wainwright & Co. Initiates Coverage On vTv Therapeutics with Buy Rating, Announces Price Target of $36

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) with a Buy and maintains $30 price target.

IBRX

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

Goldman Sachs analyst Asad Haider upgrades Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) from Neutral to Buy and raises the price target from $157 to $172.

Upgrades

Goldman Sachs Upgrades Johnson & Johnson to Buy, Raises Price Target to $172

HC Wainwright &amp; Co. analyst Sean Lee maintains CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) with a Buy and lowers the price target from $6 to $4.

CASI

HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $4

Evercore ISI Group analyst Adam Frisch initiates coverage on PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a In-Line rating and announces Price Target of $65.

PYPL

Evercore ISI Group Initiates Coverage On PayPal Holdings with In-Line Rating, Announces Price Target of $65

DPRO

Draganfly Have Been Selected As The Primary UAS Provider By Balko Technologies For Integration Of Advanced Modular LiDAR Drone Solutions

Evercore ISI Group analyst Adam Frisch initiates coverage on Global Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) with a In-Line rating and announces Price Target of $85.

Evercore ISI Group Initiates Coverage On Global Payments with In-Line Rating, Announces Price Target of $85

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Buy and maintains $720 price target.

Reiteration

ARGX

HC Wainwright & Co. Reiterates Buy on argenx, Maintains $720 Price Target

Macro Economic Events

Economics

China Commerce Ministry Said Adds 12 U.S. Entities to Export Control List

Evercore ISI Group analyst Adam Frisch initiates coverage on Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) with a In-Line rating and announces Price Target of $52.

Evercore ISI Group Initiates Coverage On Block with In-Line Rating, Announces Price Target of $52

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) with a Buy and maintains $9 price target.

MNOV

D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target

Evercore ISI Group analyst Adam Frisch initiates coverage on Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) with a In-Line rating and announces Price Target of $29.

TOST

Evercore ISI Group Initiates Coverage On Toast with In-Line Rating, Announces Price Target of $29

HC Wainwright &amp; Co. analyst Amit Dayal maintains FTC Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) with a Buy and raises the price target from $1.5 to $5.

FTCI

HC Wainwright & Co. Maintains Buy on FTC Solar, Raises Price Target to $5

Evercore ISI Group analyst Adam Frisch initiates coverage on Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a In-Line rating and announces Price Target of $80.

FOUR

Evercore ISI Group Initiates Coverage On Shift4 Payments with In-Line Rating, Announces Price Target of $80

Guidance

TRNR

Interactive Strength Raised 2025 Pro Forma Revenue By 30% To More Than $65M

D. Boral Capital analyst Jesse Sobelson maintains EON Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EONR#AMEX">EONR</a>) with a Buy and maintains $4.5 price target.

EONR

D. Boral Capital Maintains Buy on EON Resources, Maintains $4.5 Price Target

On Tuesday, April 8th, U.S. markets closed sharply lower as the S&amp;P 500 plunged below 5,000 for the first time in nearly a year, capping a four-day loss of $5.83 trillion—the steepest since the index&#8217;s inception in the 1950s. Early gains evaporated as hopes for delayed U.S. tariffs faded, and looming 104% duties on Chinese goods fueled mounting fears of a global economic downturn.
In economic data, the NFIB Small Business Optimism Index fell by 3.3 points to 97.4 in March, marking its lowest level since October 2024 and missing expectations of 101.3.
All sectors within the S&amp;P 500 ended Tuesday in the red, with consumer discretionary, materials, and energy stocks leading the day&#8217;s declines.
The Dow Jones Industrial Average declined 0.84% to 37,645.59, the S&amp;P 500 dropped 1.57% to 4,982.77, and the Nasdaq Composite fell 2.15% to close at 15,267.91.
Asia Markets Today
<ul>
<li>On Wednesday, Japan&#8217;s Nikkei 225 closed 3.78% lower at 31,764.00, led by losses in the Paper &amp; Pulp, Transport, and Communication sectors amid trade war fears, tech stock losses, a rising yen, and widespread panic selling. Nearly 90% of stocks declined as investors grappled with sharp volatility and deepening global economic uncertainty.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 was down 1.80% and closed at 7,375.00, led by losses in the Energy, Metals &amp; Mining and Resources sectors.</li>
<li>India&#8217;s Nifty 50 was down 0.59% to 22,402.45, and Nifty 500 slid 0.57% to 20,363.10.</li>
<li>The RBI cut interest rates by 25 basis points to 6% and shifted to an &#8220;accommodative&#8221; stance, citing easing inflation and slowing growth. GDP forecast was lowered amid global trade tensions.</li>
<li>China&#8217;s Shanghai Composite rose 1.31% to 3,186.81, and Shanghai Shenzhen CSI 300 increased 0.99% to 3,686.79.</li>
<li>Hong Kong&#8217;s Hang Seng Index gained 0.68% to 20,264.49.</li>
</ul>
Eurozone at 05:45 AM ET
<ul>
<li>The European STOXX 50 was down 2.77%.</li>
<li>Germany&#8217;s DAX declined 2.85%.</li>
<li>France&#8217;s CAC 40 fell 2.77%.</li>
<li>U.K.&#8217;s FTSE 100 index traded lower by 2.50%.</li>
<li>European shares fell sharply on Wednesday as steep U.S. tariffs reignited trade war concerns, dragging markets lower and pushing the STOXX 600 closer to bear territory. Rate-sensitive banks, pharmaceutical giants, energy and mining stocks led the decline.</li>
</ul>
Commodities at 05:45 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 3.89% at $57.25/bbl, and Brent was down 3.82% at $60.42/bbl.</li>
<li>Oil prices fell to a multi-year low Wednesday, marking their worst five-day losing streak in years. Global recession fears deepened amid escalating U.S.-China trade tensions and rising supply outlooks.</li>
<li>Natural Gas rose 0.55% to $3.482.</li>
<li>Gold was trading higher by 2.44% at $3,062.64, Silver was up 2.12% to $30.320, and Copper rose 2.21% to $4.2355.</li>
</ul>
U.S. Futures at 05:45 AM ET
Dow futures were down 0.40%, S&amp;P 500 futures declined 0.22%, and Nasdaq 100 futures rose 0.21%.
Forex at 05:45 AM ET
<ul>
<li>The U.S. Dollar Index declined 0.64% to 102.31, USD/JPY was down 0.70% to 145.23, and USD/AUD declined 0.95% to 1.6626.</li>
<li>The U.S. dollar slumped after President Trump&#8217;s steep tariff hike on China intensified recession fears. Markets now expect deeper Federal Reserve rate cuts, pressuring the greenback. The Dollar Index fell to levels not seen since September 2024, while safe-haven currencies like the yen and euro strengthened.</li>
</ul>
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

China Markets Up, Europe Tumbles As Trade War Escalates; Oil Hits Multi-Year Low - Global Markets Today While US Slept

As at March 31st, 2025, Osisko's cash position was approximately $63.1 million, following a $19.6 million net repayment on the Company's revolving credit facility during the first quarter. Osisko's revolving credit facility was drawn by $74.3 million at the end of March 2025, with an additional amount of $308.2 million available to be drawn plus the uncommitted accordion of C$200 million.
 &nbsp;

Osisko Gold Royalties Says It Earned 19,014 Attributable Gold Equivalent Ounces In Q1, Company Recorded Preliminary Revenues From Royalties And Streams Of $54.9M

Management

NEOG

Neogen CEO John Adent To Step Down, Will Continue To Serve Until Successor Is Appointed

Press Releases

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

Health Care

General

MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson's Disease

MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress

Earnings

MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

Contracts

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process

Comments

MeiraGTx Hldgs

MeiraGTx Hldgs (MGTX) Opzioni

MeiraGTx Hldgs (NASDAQ:MGTX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO